Skip to Main Content
Skip Nav Destination

Solid Tumor CAR-T: Making Progress in Brain Cancer

March 26, 2024

Abstract: Results from a recently completed phase I trial assessing IL-13Rα2–targeting CAR T cells in high-grade glioma—mainly recurrent glioblastoma—highlight this therapy’s potential, with 29 of 58 patients achieving stable disease or better. Meanwhile, preliminary findings from two other studies—one of a dual EGFR CAR-bearing and T-cell engager–producing therapy, the other of CAR T cells jointly aimed at IL-13Rα2 and EGFR—indicate that both approaches are safe, feasible, and can induce rapid radiographic responses.   

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal